CoChat
Sign Up
Cited by 44

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potential

Eladl, Omar·2025·Biochemical Pharmacology
DOI 10.1016/j.bcp.2025.117297
Open this paper in CoChat — free account

Abstract

Targeted protein degradation (TPD) is a transformative approach to drug discovery that enables the modulation of proteins previously considered "undruggable." Unlike traditional inhibitors, which transiently suppress protein activity, TPD harnesses the ubiquitin-proteasome system to selectively eliminate specific proteins and thereby fully abolish their activities. Two prominent approaches within TPD, Molecular Glues and PROteolysis TArgeting Chimeras (PROTACs), differ in both mechanism and therapeutic application. Molecular Glues are small molecules with low molecular weight that act as a molecular bridge, facilitating interaction between a target protein and an E3 ubiquitin ligase to enable degradation without requiring classical binding pockets. PROTACs are heterobifunctional small molecules that simultaneously engage a target protein and an E3 ligase to induce selective degradation through a catalytic mechanism. Both strategies have vastly expanded the druggable proteome and hold great promise for therapeutic interventions. This review provides a comparative overview of Molecular Glues and PROTACs, including their mechanisms, design principles, and therapeutic applications. We highlight their physicochemical properties, advantages, and limitations, as well as recent advances that are fueling the discovery of novel degraders. Through clinical advancements and case studies, we examine how these modalities are reshaping drug discovery and enabling new treatments for a variet…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bcp.2025.117297

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 7 references

Research works printed but not linked: 90

  1. Hughes, 2011, Principles of early drug discovery: Principles of early drug discovery, Br. J. Pharmacol., 162, 1239, 10.1111/j.1476-5381.2010.01127.x · DOI · Paper page
  2. Eladl, 2025, Circularization enhances RNA aptamer binding and Stability: evidence from in-cell NMR, Methods, 242, 72, 10.1016/j.ymeth.2025.07.006 · DOI
  3. Eladl, 2025, In-cell NMR reveals the first direct observation of endogenous interaction between HIV Tat protein and Tat RNA aptamer in human cells, Sci. Rep., 15, 29373, 10.1038/s41598-025-12791-0 · DOI
  4. Hoelder, 2012, Discovery of small molecule cancer drugs: successes, challenges and opportunities, Mol. Oncol., 6, 155, 10.1016/j.molonc.2012.02.004 · DOI
  5. Eladl, 2025, CRISPR interference-mediated silencing of pro-inflammatory genes in autoimmune models: functional and biophysical evaluation with sustained effects in primary human PBMCs, Int. Immunopharmacol., 163, 10.1016/j.intimp.2025.115257 · DOI
  6. Eladl, 2022, Detection of interaction between an RNA aptamer and its target compound in living human cells using 2D in-cell NMR, Chem. Commun. (Camb), 59, 102, 10.1039/D2CC05576G · DOI
  7. Eladl, 2023, Complex formation of an RNA aptamer with a part of HIV-1 Tat through induction of base triples in living human cells proven by in-cell NMR, Int. J. Mol. Sci., 24, 9069, 10.3390/ijms24109069 · DOI
  8. Zhuang, 2022, Current strategies and progress for targeting the “undruggable” transcription factors, Acta Pharmacol. Sin., 43, 2474, 10.1038/s41401-021-00852-9 · DOI
  9. Li, 2021, Protein degradation technology: a strategic paradigm shift in drug discovery, J. Hematol. Oncol., 14, 138, 10.1186/s13045-021-01146-7 · DOI
  10. Çetin, 2021, The ubiquitin-proteasome system in immune cells, Biomolecules, 11, 60, 10.3390/biom11010060 · DOI
  11. Kim, 2023, Targeted protein degradation: Principles and applications of the proteasome, Cells, 12, 1846, 10.3390/cells12141846 · DOI
  12. Konstantinidou, 2024, Molecular glues for protein-protein interactions: Progressing toward a new dream, Cell, Chem. Biol., 31, 1064
  13. Liu, 2025, Routes to molecular glue degrader discovery, Trends Biochem. Sci, 50, 134, 10.1016/j.tibs.2024.12.006 · DOI
  14. Jiang, 2024, Facilitating the development of molecular glues: Opportunities from serendipity and rational design, Eur. J. Med. Chem., 263, 10.1016/j.ejmech.2023.115950 · DOI
  15. Toriki, 2023, Rational chemical design of molecular glue degraders, ACS Cent. Sci., 9, 915, 10.1021/acscentsci.2c01317 · DOI
  16. Pei, 2019, Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery, RSC Adv., 9, 16967, 10.1039/C9RA03423D · DOI
  17. Sun, 2019, PROTACs: great opportunities for academia and industry, Signal Transduct. Target. Ther., 4, 64, 10.1038/s41392-019-0101-6 · DOI
  18. Békés, 2022, PROTAC targeted protein degraders: the past is prologue, Nat. Rev. Drug Discov., 21, 181, 10.1038/s41573-021-00371-6 · DOI · Paper page
  19. Hu, 2022, Recent developments in PROTAC-mediated protein degradation: from bench to clinic, Chembiochem, 23, 10.1002/cbic.202100270 · DOI · Paper page
  20. Ge, 2024, Development of PROTACs using computational approaches, Trends Pharmacol. Sci., 45, 1162, 10.1016/j.tips.2024.10.006 · DOI
  21. Soini, 2022, Molecular glues to stabilise protein-protein interactions, Curr. Opin. Chem. Biol., 69, 10.1016/j.cbpa.2022.102169 · DOI
  22. Zhong, 2022, Emerging targeted protein degradation tools for innovative drug discovery: from classical PROTACs to the novel and beyond, Eur. J. Med. Chem., 231, 10.1016/j.ejmech.2022.114142 · DOI
  23. Liu, 2022, An overview of PROTACs: a promising drug discovery paradigm, Mol. Biomed., 3, 46, 10.1186/s43556-022-00112-0 · DOI
  24. Zagidullin, 2020, Novel approaches for the rational design of PROTAC linkers, Explor. Target. Antitumor Ther., 1, 381, 10.37349/etat.2020.00023 · DOI
  25. Dong, 2024, Characteristic roadmap of linker governs the rational design of PROTACs, Acta Pharm. Sin. B, 14, 4266, 10.1016/j.apsb.2024.04.007 · DOI · Paper page
  26. Petzold, 2016, Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase, Nature, 532, 127, 10.1038/nature16979 · DOI · Paper page
  27. Maneiro, 2021, PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs, Prog. Med. Chem., 60, 67, 10.1016/bs.pmch.2021.01.002 · DOI
  28. Li, 2022, Molecular glues: Capable protein-binding small molecules that can change protein-protein interactions and interactomes for the potential treatment of human cancer and neurodegenerative diseases, Int. J. Mol. Sci., 23, 6206, 10.3390/ijms23116206 · DOI
  29. Syahputra, 2025, PROTAC delivery strategies for overcoming physicochemical properties and physiological barriers in targeted protein degradation, Pharmaceutics, 17, 10.3390/pharmaceutics17040501 · DOI · Paper page
  30. Cecchini, 2022, Linkers as game-changers in PROTAC Technology: Emphasizing general trends in PROTAC Pharmacokinetics for their rational design, Chimia (aarau), 76, 341, 10.2533/chimia.2022.341 · DOI
  31. Wurz, 2023, Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation, Nat. Commun., 14, 4177, 10.1038/s41467-023-39904-5 · DOI
  32. Schwalm, 2023, Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization, Cell, Chem. Biol., 30, 753
  33. Weagel, 2022, Molecular glues: enhanced protein-protein interactions and cell proteome editing, Med. Chem. Res., 31, 1068, 10.1007/s00044-022-02882-2 · DOI
  34. Kim, 2022, Targeted protein degradation to overcome resistance in cancer therapies: PROTAC and N-degron pathway, Biomedicines, 10, 2100, 10.3390/biomedicines10092100 · DOI
  35. Simpson, 2022, Target protein localization and its impact on PROTAC-mediated degradation, Cell, Chem. Biol., 29, 1482
  36. Yang, 2024, Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy, Signal Transduct. Target. Ther., 9, 275, 10.1038/s41392-024-01983-1 · DOI
  37. Juan, 2021, Options to improve the action of PROTACs in cancer: Development of controlled delivery nanoparticles, Front. Cell Dev. Biol., 9
  38. Tan, 2024, Molecular glue-mediated targeted protein degradation: a novel strategy in small-molecule drug development, iScience, 27, 10.1016/j.isci.2024.110712 · DOI · Paper page
  39. Benet, 2016, BDDCS, the rule of 5 and drugability, Adv. Drug Deliv. Rev., 101, 89, 10.1016/j.addr.2016.05.007 · DOI
  40. Apprato, 2024, Exploring the chemical space of orally bioavailable PROTACs, Drug Discov. Today, 29, 10.1016/j.drudis.2024.103917 · DOI
  41. Goracci, 2020, Understanding the metabolism of PROteolysis TArgeting Chimeras (PROTACs): the next step toward pharmaceutical applications, J. Med. Chem., 63, 11615, 10.1021/acs.jmedchem.0c00793 · DOI
  42. Wang, 2024, New-generation advanced PROTACs as potential therapeutic agents in cancer therapy, Mol. Cancer, 23, 110, 10.1186/s12943-024-02024-9 · DOI
  43. Galustian, 2009, Lenalidomide: a novel anticancer drug with multiple modalities, Expert Opin. Pharmacother., 10, 125, 10.1517/14656560802627903 · DOI
  44. Chirnomas, 2023, Protein degraders enter the clinic - a new approach to cancer therapy, Nat. Rev. Clin. Oncol., 20, 265, 10.1038/s41571-023-00736-3 · DOI · Paper page
  45. Neklesa, 2019, ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer, J. Clin. Oncol., 37, 259, 10.1200/JCO.2019.37.7_suppl.259 · DOI
  46. Gao, 2022, Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC), J. Clin. Oncol., 40, 17, 10.1200/JCO.2022.40.6_suppl.017 · DOI
  47. Wang, 2022, The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options, Cancer Metastasis Rev., 41, 975, 10.1007/s10555-022-10066-y · DOI
  48. Lu, 2014, The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins, Science, 343, 305, 10.1126/science.1244917 · DOI · Paper page
  49. Schafer, 2018, Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus, Ann. Rheum. Dis., 77, 1516, 10.1136/annrheumdis-2017-212916 · DOI · Paper page
  50. Shen, 2020, Casein kinase 1α as a regulator of Wnt-driven cancer, Int. J. Mol. Sci., 21, 5940, 10.3390/ijms21165940 · DOI
  51. Zhao, 2021, Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma, Biochem Biophys Res Commun., 549, 150, 10.1016/j.bbrc.2021.02.110 · DOI
  52. Bonazzi, 2023, Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy, Cell, Chem. Biol., 30, 235
  53. Crunkhorn, 2023, Developing an IKZF2 glue degrader, Nat. Rev. Drug Discov., 22, 271
  54. Snyder, 2025, Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis TArgeting Chimera androgen receptor degrader, Mol. Cancer Ther., 24, 511, 10.1158/1535-7163.MCT-23-0655 · DOI
  55. Wang, 2025, Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML, Blood, 10.1182/blood.2024027117 · DOI
  56. Li, 2025, Decoy-PROTAC for specific degradation of “Undruggable” STAT3 transcription factor, Cell Death Dis., 16, 197, 10.1038/s41419-025-07535-x · DOI
  57. Kong, 2025, Correction: BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression, Oncogene, 44, 557, 10.1038/s41388-024-03250-7 · DOI
  58. Starodub, 2022, Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors, J. Clin. Oncol., 40, 10.1200/JCO.2022.40.16_suppl.TPS3171 · DOI
  59. Lim, 2023, Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models, Blood Adv., 7, 92, 10.1182/bloodadvances.2022008121 · DOI
  60. Alu, 2022, BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies, J. Hematol. Oncol., 15, 138, 10.1186/s13045-022-01353-w · DOI
  61. Robbins, 2024, Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of bruton’s tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies, J. Med. Chem., 67, 2321, 10.1021/acs.jmedchem.3c01007 · DOI
  62. Lee, 2023, Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology, Mol. Neurodegener., 18, 41, 10.1186/s13024-023-00630-7 · DOI
  63. Zhou, 2025, Advancements in proteolysis targeting chimeras for targeted therapeutic strategies in Alzheimer’s disease, Mol. Neurobiol., 62, 9686, 10.1007/s12035-025-04838-0 · DOI
  64. Kadier, 2024, PROTAC-mediated HDAC7 protein degradation unveils its deacetylase-independent proinflammatory function in macrophages, Adv. Sci. (weinh.), 11
  65. Yamamoto, 2022, Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders, Chem. Soc. Rev., 51, 6234, 10.1039/D2CS00116K · DOI
  66. Nutt, 2024, Strengthening molecular glues: Design strategies for improving thalidomide analogs as cereblon effectors and anticancer agents, Drug Discov. Today, 29, 10.1016/j.drudis.2024.104010 · DOI
  67. Hu, 2024, Molecular glue degrader for tumor treatment, Front. Oncol., 14, 10.3389/fonc.2024.1512666 · DOI
  68. Hemkens, 2023, Industry perspective on the nonclinical safety assessment of heterobifunctional degraders, Drug Discov. Today, 28, 10.1016/j.drudis.2023.103643 · DOI
  69. Asano, 2023, Oral absorption of middle-to-large molecules and its improvement, with a focus on new modality drugs, Pharmaceutics, 16, 10.3390/pharmaceutics16010047 · DOI
  70. Kofink, 2022, A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo, Nat. Commun., 13, 5969, 10.1038/s41467-022-33430-6 · DOI
  71. Riching, 2022, The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation, Chem. Soc. Rev., 51, 6210, 10.1039/D2CS00339B · DOI
  72. Poongavanam, 2022, Linker-dependent folding rationalizes PROTAC cell permeability, ChemRxiv
  73. Abeje, 2025, Impact of linker composition on VHL PROTAC cell permeability, J. Med. Chem., 68, 638, 10.1021/acs.jmedchem.4c02492 · DOI
  74. Cieślak, 2023, Cereblon-recruiting PROTACs: will new drugs have to face old challenges?, Pharmaceutics, 15, 10.3390/pharmaceutics15030812 · DOI
  75. R. Pujari, U. Soni, Toxicological aspects of PROTACs, in: PROTAC-Mediated Protein Degradation: A Paradigm Shift in Cancer Therapeutics, Springer Nature Singapore, Singapore, 2024: pp. 193–208. · DOI
  76. Li, 2024, Structure-based Design of “Head-to-Tail” Macrocyclic PROTACs, JACS Au, 4, 4866, 10.1021/jacsau.4c00831 · DOI
  77. Zheng, 2021, Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP, J. Med. Chem., 64, 7839, 10.1021/acs.jmedchem.1c00649 · DOI
  78. Kandarpa, 2020, AML-397: Preclinical efficacy of a PROTAC-based MDM2 degrader in AML models, Clin. Lymphoma Myeloma Leuk., 20, S212
  79. Ahn, 2021, LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation, Nat. Chem. Biol., 17, 937, 10.1038/s41589-021-00770-1 · DOI
  80. Xiao, 2025, A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy, Nat. Commun., 16, 1388, 10.1038/s41467-025-56648-6 · DOI
  81. Lee, 2024, Targeted degradation of SNCA/α-synuclein aggregates in neurodegeneration using the AUTOTAC chemical platform, Autophagy, 20, 463, 10.1080/15548627.2023.2274711 · DOI
  82. Li, 2022, DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs, Nat. Commun., 13, 7133, 10.1038/s41467-022-34807-3 · DOI · Paper page
  83. Jia, 2025, The role of RNA binding proteins in cancer biology: a focus on FMRP, Genes Dis., 12
  84. An, 2024, Crbn-based molecular Glues: Breakthroughs and perspectives, Bioorg. Med. Chem., 104, 10.1016/j.bmc.2024.117683 · DOI
  85. Hicks, 2012, Lipid rafts and Alzheimer’s disease: protein-lipid interactions and perturbation of signaling, Front. Physiol., 3, 189, 10.3389/fphys.2012.00189 · DOI
  86. Kramer, 2022, Expanding the landscape of E3 ligases for targeted protein degradation, Curr. Res. Chem. Biol., 2, 10.1016/j.crchbi.2022.100020 · DOI
  87. Reynders, 2021, PHOTACs enable optical control of protein degradation, Methods Mol. Biol., 2365, 315, 10.1007/978-1-0716-1665-9_17 · DOI
  88. Yoosefian, 2016, The role of boron nitride nanotube as a new chemical sensor and potential reservoir for hydrogen halides environmental pollutants, Superlattices Microstruct., 98, 325, 10.1016/j.spmi.2016.08.049 · DOI
  89. Moon, 2023, Cancer-specific delivery of proteolysis-targeting chimeras (PROTACs) and their application to cancer immunotherapy, Pharmaceutics, 15, 411, 10.3390/pharmaceutics15020411 · DOI
  90. Gao, 2023, Stimuli-activatable PROTACs for precise protein degradation and cancer therapy, Sci. Bull. (Beijing), 68, 1069, 10.1016/j.scib.2023.04.028 · DOI

Cited by

Sorted by citations

Metadata

Authors
Eladl, O.
Venue
Biochemical Pharmacology
Publisher
Elsevier BV
Published
2025-12
Volume
242
Pages
117297
ISSN
0006-2952
DOI
10.1016/j.bcp.2025.117297
Cited by
44
References
7
Language
en
Licence
Funders
Zagazig University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review